Fingolimod EP Impurity E

Fingolimod promotes angiogenesis and attenuates ischemic brain damage via modulating microglial polarization
KeShanga1JiaHeb1JingZoubChuanQinaLiLincLuo-QiZhouaLin-LinYangbLong-JunWudWeiWangaKe-BinZhanbDai-ShiTiana
Brain Research Volume 1726, 1 January 2020, 146509
 
Rapid Determination of Fingolimod Hydrochloride‑Related Substances and Degradation Products in API and Pharmaceutical Dosage Forms by Use of a Stability‑Indicating UPLC Method
N. Rajan · K. Anver Basha
Chromatographia (2014) 77:1545–1552
 
Development and validation of Immunomodulating drug Fingolimod by RPHPLC method with detailed force degradation study
Ravi V Ghediya1,2, Madhavi Patel1,2,3, Darshana Pandya1,2, Anamik K Shah1,2, Ranjan C Khunt
Chemistry & Biology Interface, 2016, 6, 4, 210-223

Fingolimod EP Impurity E is chemically 2-(2-(4-Octylphenethyl)-4-octylphenethyl)-2-aminopropane-1,3-diol ; 2-amino-2-(4-octyl-2-(4-octylphenethyl)phenethyl)propane-1,3-diol. It is also known as Fingolimod ortho-octylphenyl Impurity ; Fingolimod 2-Phenethyl Analog ; . Fingolimod EP Impurity E is supplied with detailed characterization data compliant with regulatory guideline. Fingolimod EP Impurity E can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Fingolimod.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.